Genetic Confirmation of Atovaquone-Proguanil–Resistant Plasmodium falciparum Malaria Acquired by a Nonimmune Traveler to East Africa
E Schwartz, S Bujanover, KC Kain - Clinical infectious diseases, 2003 - academic.oup.com
E Schwartz, S Bujanover, KC Kain
Clinical infectious diseases, 2003•academic.oup.comWe report a case of atovaquone-proguanil–resistant Plasmodium falciparum malaria
acquired by a nonimmune traveler to Kenya. Recurrent parasitemia occurred 30 days after
directly observed therapy with a combination of atovaquone and proguanil. Treatment failure
was confirmed by genetic fingerprinting and sequencing. The primary isolate had wild-type
sequence of cytochrome b; however, the recrudescent isolate had a single mutation at
position 268 (Tyr268Ser).
acquired by a nonimmune traveler to Kenya. Recurrent parasitemia occurred 30 days after
directly observed therapy with a combination of atovaquone and proguanil. Treatment failure
was confirmed by genetic fingerprinting and sequencing. The primary isolate had wild-type
sequence of cytochrome b; however, the recrudescent isolate had a single mutation at
position 268 (Tyr268Ser).
Abstract
We report a case of atovaquone-proguanil–resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to Kenya. Recurrent parasitemia occurred 30 days after directly observed therapy with a combination of atovaquone and proguanil. Treatment failure was confirmed by genetic fingerprinting and sequencing. The primary isolate had wild-type sequence of cytochrome b; however, the recrudescent isolate had a single mutation at position 268 (Tyr268Ser).
Oxford University Press以上显示的是最相近的搜索结果。 查看全部搜索结果